Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloride valine-naphthoquinone (4b) is a synthetic small molecule naphthoquinone amino acid derivative investigated for its potential antitumorigenic activity, particularly against cervical cancer. Synthesized using microwave-assisted methods, the compound incorporates a valine moiety and a chlorine atom into a 1,4-naphthoquinone scaffold. Its mechanism of action is primarily attributed to its redox-active properties, which facilitate the generation of reactive oxygen species (ROS) and lead to cytotoxicity in tumorigenic cell lines. In preclinical studies, compound 4b demonstrated significant antiproliferative effects against both HPV-positive (SiHa, CaLo) and HPV-negative (C33-A) cervical cancer cells, often showing potency superior to conventional agents like paclitaxel in specific cellular contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloride valine-naphthoquinone (4b).